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ABSTRACT 
 
THE EFFECTIVENESS OF A PREOPERATIVE MULTIMODAL ANTIEMETIC  
 
REGIMEN ON REDUCING EARLY POSTOPERATIVE NAUSEA AND VOMITING  
 
IN TOTAL JOINT ARTHROPLASTY PATIENTS 
 
by Jerry Mosley Jr.  
 
December 2015 
 
Postoperative nausea and vomiting (PONV) occurs frequently in all types of 
surgeries including after total joint orthopedic procedures. The resulting PONV can lead 
to many unwanted occurrences including immobilization, distress, and many serious 
adverse health complications. These unwanted occurrences may then lead to increased 
cost to the patient and healthcare facility. Administration of a preoperative multimodal 
regimen known to reduce PONV has the potential to reduce such unwanted anesthetic 
side effects influencing a reduction in overall healthcare cost. The purpose of this study is 
to determine the effectiveness of the preoperative kit which includes the administration of 
metoclopramide, famotidine, ondansetron, and levoduboisine on PONV in patients 
undergoing total knee arthroplasy (TKA) and total hip arthroplasty (THA). Inclusion 
criteria would be patients between the ages of 18 to 60, male and female, American 
Society of Anesthesiologists (ASA) I and II health score, undergoing TKA or THA, and 
receiving the standard preoperative kit. Exclusion criteria would be those patients less 
than 18 or older than 60 years of age, ASA III or greater, hip or knee revisions, having 
significant blood loss, or significant hypotension. A retrospective chart review will be 
completed and data collected with respect to this specific patient population and the 
presence of PONV and need for antiemetic use. The percentage of PONV will be 
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calculated for the specified patient population and compared to expected PONV 
percentage rates from evidence-based literature. 
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CHAPTER I 
INTRODUCTION 
Statement of the Problem 
In the United States (US) over 50 million patients undergo surgery per year and 
more than 100 million patients worldwide (Centers of Disease Control and Prevention 
[CDC], 2014). The total amount of total hip and total joint arthroplasty surgeries 
encompass over one million alone in the US (CDC, 2014). Postoperative nausea and 
vomiting is one of the most commonly reported adverse effects of anesthesia and patients 
with no known risk factors still carry a 10% risk of PONV (Smith, Smith, & Smith, 
2012). Postoperative nausea and vomiting is nausea and/or vomiting occurring within 24 
hours after surgery (Kore, Wondwossen, & Amare, 2013). Early PONV is nausea and/or 
vomiting that occurs in the first 2 to 6 hours after surgery and usually occurs in the phase 
I post-anesthesia care unit. PONV is one of the most commonly reported adverse effects 
of anesthesia and affects between 20% and 30% of adult patients undergoing a surgical 
procedure and as many as 70% to 80% of high risk adult patients (Kore et al., 2013). 
Adverse effects of PONV can include aspiration, wound suture opening, prolonged 
hospital stays, increased patient discomfort and dissatisfaction, unanticipated admission 
after outpatient surgery, and delayed return of a patient's ability to function in daily 
activities (Ku & Ong, 2003). PONV can lead to inflated health care costs related to 
extended post anesthesia care unit (PACU) stays, prolonged nursing care, and over-night 
admissions (Ku & Ong, 2003).  Research has shown that the use of several different 
antiemetic medications can reduce the occurrence of PONV from over 52% to less than 
30% in certain populations (Chatterjee, Rudra, & Sengupta, 2011). The purpose of this 
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study is to determine the effectiveness of the preoperative administration of anti-nausea 
medications on early PONV in patients undergoing total hip arthroplasty and total knee 
arthroplasty. Realizing the potential monetary loss to healthcare facilities for extended 
care, the future loss in revenue due to patient dissatisfaction, and effect on patient health, 
one would appreciate the need to complete such a study to gain needed insight into 
reducing PONV. 
Conceptual and Theoretical Framework 
The development and use of nursing theory is geared towards the description, 
prediction, and explanation between two or more objects, properties, or events (Butts & 
Rich, 2011). Past benefits of nursing theory include the substitution of medical theory for 
a more appropriate nursing theory and the growth and increase of nursing knowledge 
(McKenna, 2005). Middle-range theory is a type of theory that is described as more 
concrete, narrower in scope, less abstract, and has fewer concepts than other theories 
(Butts, 2011; Fawcett, 2005). These reasons make middle-range theory more appropriate 
in a clinical setting (Lenz, 1998). Prescriptive theory is a type of middle-range theory that 
can be associated with a graduate level project related to a clinical setting.  
McKenna and Slevin (2008) defined prescriptive theory as a scientific theory also 
known as “knowledge utilization.” Other theorists label prescriptive theory as practice 
theory and even situation-producing theory (Butts, 2011). Prescriptive theory is a type of 
middle-range theory that encompasses descriptive, explanatory, and predictive theory 
(Butts, 2011).  This theory is applicable to classify and describe events, explain the 
relationship between concepts, and to predict cause-and-effect relationships (Butts, 
2011). Prescriptive theory, also known as practice theory, should prescribe the scientific 
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interventions of a clinical nurse (McKenna, 2005). Nursing theories are assumed to 
improve problem solving, increase patient satisfaction, guide and justify nursing actions, 
and direct research towards clinical nursing needs (McKenna, 2005). Practice theory 
should have a cause-effect relationship that can be empirically tested and replicated 
(McKenna, 2005). This theory is also based on causal agents that can be manipulated by 
the professional with relevance to achieving practice goals that are within the practice 
guidelines (McKenna, 2005). 
The application of prescriptive theory to this project will hopefully demonstrate 
that the administration of a preoperative antiemetic regimen to total knee arthroplasy 
(TKA) and total hip arthorplasty (THA) patients will reduce the occurrence of PONV and 
the use of rescue emetics. Using prescriptive or practice theory will include the use of 
descriptive, explanatory, and predictive theories, since prescriptive theory is composed of 
such (Butts, 2011). Descriptive theory will be used to gain knowledge into the efficacy of 
the administration of a preoperative antiemetic regimen to surgical patients for PONV to 
reduce nausea and/or vomiting and its effect on the healthcare system; explanatory theory 
will help explain the relationship between the administration of a preoperative antiemetic 
regimen and the reduction of PONV; and predictive theory will be used to foresee cause-
and-effect relationships. The use of a middle-ranged theory such as prescriptive theory 
will help classify, explain, and predict PONV. The application of prescriptive theory in 
combination with a retrospective chart review will hopefully show the benefits of the 
administration of a preoperative antiemetic regimen for PONV and lead to a better 
understanding and a decrease in such an unwanted occurrence. The overall goal would be 
a standard of care, or protocol, composed of the administration of a preoperative 
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prophylactic antiemetic regimen to a certain population undergoing a certain surgical 
procedure to reduce PONV. 
Prescriptive theory is an appropriate theory to describe what PONV is, explain the 
relationship between a certain population at risk for PONV and some of the causes of 
PONV, the reasoning behind the administration of a multimodal preoperative antiemetic 
regimen for PONV, and identifying those at risk for PONV and predicting a positive 
outcome with proper treatment. 
Needs Assessment 
 Postoperative nausea and vomiting (PONV) is still one of the most widely arising 
complications even with numerous advances in medicine. Postoperative nausea and 
vomiting in patients undergoing total hip and total knee surgery can lead to aspiration, 
electrolyte imbalances, immobility, thromboembolic disease, emotional distress, and 
discomfort (Peters, Brayton, & Erickson, 2006). With vast advances in surgical 
technique, surgical equipment, and pharmaceuticals, surgical patients recover in a shorter 
amount of time than in the past. Less time recovering in the post anesthesia care unit and 
in the hospital not only equates to less cost to the patient and healthcare facility but also 
to an increase in patient satisfaction. 
 In the past much of healthcare was based upon the treatment of those already 
infected and geared towards treating the sick. Healthcare has now shifted towards 
preventative treatment in the hopes of reducing the amount of unwanted occurrences and 
in turn reducing healthcare costs. Providing a prophylactic preoperative antiemetic 
regimen to surgical patients undergoing total hip and total knee arthroplasty surgeries can 
reduce undesirable outcomes as well as overall cost to the client and healthcare 
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establishment. Determining how proficient the use of an antiemetic regimen consisting of 
metoclopramide, famotidine, ondansetron, and levoduboisine leads to a decrease in early 
PONV in total knee and total hip arthroplasty patients will be extremely valuable. The 
results may lead to an increased use of such an antiemetic regimen for all total knee and 
total hip surgeries as well as other surgeries that involve high risk PONV patients. This in 
turn will lead to a decrease in patient and facility cost, a decrease in patient recovery time 
in the post anesthesia care unit and recovery time on the floor unit, as well as a decrease 
in the amount of time the patient can return to normal functioning in society or 
employment. 
PONV Implications 
It is estimated that an episode of PONV will increase a patient’s stay in the post 
anesthesia care unit (PACU) by about 25 minutes to one hour. (Chatterje et al., 2011; 
Parra-Sanchez et al., 2012). Patient’s polled before surgery were willing to pay 
approximately $56 in United States (US) currency for a medication that would 
completely prevent nausea, and were willing to pay approximately $100 in US currency 
once they developed PONV (Tong, Sloan, Dear, El-Moalem, & Lubarsy, 2000). Patient’s 
polled at surgical centers also ranked vomiting as the most undesirable manifestation, 
even over pain, residual weakness, and recall (Smith et al., 2012). An incremental cost 
per patient of $75 in US currency accrued for those patients that experienced PONV in an 
ambulatory setting (Parra-Sanchez et al., 2012). Also of importance is the cost to an 
ambulatory surgery center for the treatment of acquired PONV which can be 
approximated to over $1000 US currency per patient (Sanchez, Hirsch, Carroll, & 
Miederhoff, 1994). 
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CHAPTER II 
REVIEW OF LITERATURE 
Nausea and Vomiting 
Nausea is an uncomfortable sensation of an approaching vomiting occurrence 
(Watcha & White, 1992). It is often associated with symptoms such as salivation, 
tachycardia, swallowing, burping, and sweating (Watcha & White, 1992). Vomiting is a 
complicated process, mediated by a central coordinating vomiting center, residing in the 
Emetic Center (EC) in the brainstem (Andrews, 1992). This area receives inputs from the 
pharynx, GI tract, mediastinum, higher cortical centers including the visual, olfactory, 
gustatory, vestibular centers, and the Chemoreceptor Trigger Zone (CTZ) (Andrews, 
1992). CTZ activity is modified by a variety of receptors (Andrews, 1992). There are at 
least four major receptor areas that are believed to be involved in PONV and these areas 
are the cholinergic (muscarinic) receptors, dopaminergic (D2) receptors, histaminergic 
(H1) receptors, and serotonergic (5HT3) receptors (Chatterje et al., 2011). The 
cholinergic receptors are found in the vomiting center and vestibular nuclei, serotonergic 
and dopaminergic are found in the area postrema, and last the histaminergic are located in 
the nucleus tractus (Chatterje et al., 2011). The CTZ receives input from these receptors 
and the EC initiates vomiting (Andrews, 1992). Most anti-nausea treatments act by a 
direct or indirect antagonizing of chemicals on receptors in the CTZ, which reduce 
PONV (Chandrakantan & Glass, 2011). 
Etiology of PONV 
The etiology of PONV is multifactorial consisting of individual, anesthetic, and 
surgical risk factors (McCracken, Houston, & Lefebvre, 2008). Individual risk factors 
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include the female gender, positive history of PONV or motion sickness, nonsmoking 
status, and young age (McCracken et al., 2008). Anesthetic considerations include the use 
of inhalational agents, nitrous oxide, opioids, and neostigmine (McCracken et al., 2008). 
Surgical risk factors include gynecological procedures, laparoscopic procedures, 
orthopedic procedures, and duration of the surgery (McCracken et al., 2008). Other 
possible risk factors include obesity, dehydration, low blood pressure, and a history of 
migraine headaches (McCracken et al., 2008). Severe nausea and vomiting post total joint 
procedures are common due to the use of regional anesthetics, general anesthetics, and 
narcotics and have a reported incidence of 20% to 83% (Dilorio, Sharkey, Hewitt, & 
Parvizi, 2010). In spinal anesthesia there are several different mechanisms that can be 
attributed to PONV  including hypotension (systolic blood pressure less than 80 mmHg), 
a block higher than the fifth thoracic segment, and the addition of a vasoconstrictor or 
narcotic to the local anesthetic (Borgeat, Ekatodramis, & Schenker, 2003). Hypotension 
is very common in neuraxial anesthesia and PONV may be attributed to the activation of 
the vomiting centers by brain ischemia (Borgeat et al., 2003). Gut ischemia may also lead 
to nausea and vomiting by the release of emetogenic substances like serotonin from the 
intestines (Borgeat et al., 2003). Neuraxial agents also cause sympathetic blockade which 
results in unopposed vagal action resulting in gastrointestinal hyperactivity which is 
believed to contribute to PONV (Borgeat et al., 2003). The addition of narcotics such as 
morphine and fentanyl to the local anesthetic used in regional anesthesia may lead to 
PONV by activating the chemoreceptive trigger zone (Borgeat et al., 2003). Opioids also 
decrease muscle tone and peristalsis, thereby reducing gastric emptying, and can lead to 
distention and vomiting (Whelan, 2012). General anesthesia and the use of volatile 
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anesthetics may increase PONV by two fold through decreasing serum levels of 
anandamide, which works on receptors that suppress nausea and vomiting (Whelan, 
2012). Some studies have even shown up to a 27% occurrence in PONV with the use of 
inhalational agents (Kenny, 2004).   
PONV Recognition Tools 
The Apfel Score (Appendix A) is a useful tool in recognizing those at the highest 
risk for PONV (Apfel, Kranke, Eberhart, Roos, & Roewer, 2002). This scoring system is 
composed of a four point scale with one point given for each positive characteristic 
(Apfel et al., 2002). The four characteristics are female sex, history of motion sickness or 
post-operative nausea or vomiting, being a non-smoker, and the anticipated use of opioids 
(Apfel et al., 2002). The presence of 0, 1, 2, 3, or 4 risk factors equate to 10%, 20%, 40%, 
60%, and 80% respectively (Apfel et al., 2002). Another tool in recognizing those at the 
highest risk for PONV is Koivuranta Score (Appendix B) which is composed of a five 
point scale with one point given for each positive characteristic (Koivuranta, Laara, 
Snare, & Alahuhta, 1997). The five characteristics are female sex, history of motion 
sickness, history of post-operative nausea or vomiting, duration of surgery longer than 
sixty minutes, and being a non-smoker (Koivuranta et al., 1997). The presence of 0, 1, 2, 
3, 4, or 5 risk factors equate to a 17%, 18%, 42%, 54%, 74%, and 87% respectively 
(Koivuranta et al., 1997). 
Multimodal Antiemetic Regimen 
 Metoclopramide (Reglan) is a benzamide that prevents PONV by increasing 
lower esophageal sphincter tone, which promotes gastric emptying by increasing small 
bowel and gastric motility (Nagelhout & Plaus, 2014).  Metoclopramide is believed to 
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exert its effects on cholinergic, serotonergic, and dopaminergic receptors with more 
profound effects acting as a dopaminergic receptor antagonist (Nagelhout & Plaus, 2014).  
Through research it has been found to be insignificant in the prevention of PONV unless 
it is combined with other antinausea medications including Ondansetron or 
Dexamethasone (Nagelhout & Plaus, 2014).  An extremely advantageous aspect of 
Reglan is the lack of sedative traits, while containing an unwanted side effect of 
extrapyramidal symptoms and dystonia (Nagelhout & Plaus, 2014).  Famotidine (Pepcid) 
is a histamine 2 antagonist (H2 blocker) that provides the best duration of action versus 
side effect profile (Nagelhout & Plaus, 2014). Famotidine reduces gastric volume by 
reducing gastrin-induced acid production and raises the pH of gastric contents as well 
(Nagelhout & Plaus, 2014). Ondansetron (Zofran) is a selective serotonin type 3 receptor 
antagonist (5HT3) that is widely used as a lone antiemetic or in conjunction with other 
antiemetics (Nagelhout & Plaus, 2014).  Ondansetron has the ability to reduce PONV and 
has been shown to have little effect on cardiovascular, extrapyramidal symptoms, or 
sedation (Kenny, 2004). Some minimal side effects common to the serotonin antagonists 
include headache, lightheadedness, dizziness, and constipation (Chatterje et al., 2011). 
Levoduboisine (Scopolamine) is an anticholinergic agent that acts on the muscarinic and 
histaminic receptors of the vestibular apparatus and the nucleus of the tractus solitarus to 
reduce the incidence of PONV (Chatterje et al., 2011).  Levoduboisine has a high 
incidence of side effects causing sedation, dry mouth, drowsiness, contact dermatitis, and 
visual disturbances (Nagelhout & Plaus, 2014).  
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Multimodal Drug Therapy 
 The use of a multimodal drug therapy was initiated due to the limiting effects of 
single drug therapy and the overall reduction of PONV with more than one medication 
(Chandrakantan & Glass, 2011). There are several receptor systems involved in the 
initiation and treatment of PONV, and a combination of those drugs acting at the 
different receptors would have greater efficacy than a single drug (Chandrakantan & 
Glass, 2011). The use of more than one anti-emetic that works on the same receptor does 
not decrease the rate of PONV but the incidence of side-effects does increase 
(Chandrakantan & Glass, 2011). Therefore, the multimodal technique offers the benefits 
of enhanced PONV reduction with a lower incidence of side-effects (Chandrakantan & 
Glass, 2011). There is also a correlation between the number of different antiemetics 
used, assuming they each work on the different receptors, and the reduction of PONV. 
For each antiemetic used up to a total of four, there is a 10% decrease for each after the 
first administered antiemetic medication up to a total of 30% (Chandrakantan & Glass, 
2011). 
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CHAPTER III 
METHODOLOGY 
Setting 
The setting for this retrospective chart analysis will be at a specialty facility in the 
Southeastern United States. This facility encompasses a 10-bed preoperative area, six 
operating rooms, a 10-bed postoperative recovery room, and a 30-bed orthopedic patient 
care floor. Patient information and record-keeping is accomplished by using Electronic 
Patient Integrated Care (EPIC) software.  
Target Outcome 
Based upon the Apfel and Koivuranta Postoperative Nausea and Vomiting 
(PONV) Scoring Systems, if no antiemetics are administered, all patients undergoing a 
surgical procedure will have between a 10% and 80% risk for PONV and between a 17% 
and 87% risk for PONV respectively (Apfel, 2002; Koivuranta, 1997). Postoperative 
nausea and vomiting in patients undergoing total hip and total knee surgery can lead to 
aspiration, electrolyte imbalances, immobility, thromboembolic disease, emotional 
distress, and discomfort (Peters, Brayton, & Erickson, 2006). An incremental cost per 
patient of $75 in United States (US) currency accrued for those patients that experienced 
PONV in an ambulatory setting (Parra-Sanchez et al., 2012). Also of importance is the 
cost to an ambulatory surgery center for the treatment of acquired PONV which can be 
approximated to over $1000 US currency per patient (Sanchez, Hirsch, Carroll, & 
Miederhoff, 1994). Today these costs would be more accurately listed as an incremental 
cost per patient of $77.30 in US currency and to over $1600 US currency to an 
ambulatory surgery center for treatment of PONV (Measuring Worth, 2015). 
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The desired goal of this capstone study is to determine the effectiveness of a 
preoperative prophylactic multimodal regimen on reducing early PONV in TKA and 
THA patients. If results are favorable, the desired outcome of the project is to provide 
information for the future development of a policy change in healthcare facilities and/or 
to provide a documented and researched source for verification. Results in a lower rate of 
PONV with this predetermined regimen can lead to a protocol for other institutions to 
incorporate into practice. Use of such an antiemetic regimen to prevent PONV can reduce 
healthcare costs to facilities and patients as well as decrease deteriorative incidents and 
increase patient comfort, safety, and satisfaction. 
Limitations 
The following are limitations to the accuracy of this capstone project. Individuals 
have been shown to exhibit different levels of PONV tolerance. While some are able to 
tolerate the feeling others are not. Those able to tolerate differing levels of PONV might 
request not to receive any antiemetic medications in the post anesthesia care unit 
(PACU). Completing a retrospective chart review does not allow direct observation of the 
patients. If no anti-emetics are given there will be no identification of early PONV, even 
if this transpires, unless the PACU nurse documents such.  Also there are many different 
ways to treat PONV besides anti-emetic medications and if those non- medicinal 
therapies are administered, such therapies will not be identified as PONV treatments. The 
recognition of PONV may also be blunted by the administration of narcotics and the 
triggering of a sleep state. This patient may not exhibit signs and symptoms of PONV 
until becoming more alert on the recovery floor past the early PONV timeframe. Last, 
human administration and recording of the type and amount of all medications to patients 
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are provided by human caregivers into computer systems. There is always a chance of 
human error in documentation, administration, and the quantity of administration. 
Population 
The setting for this retrospective chart analysis will be at a specialty facility in the 
Southeast region of the United States. A retrospective chart analysis shall be conducted 
on a range of between 50 to 60 patients undergoing total knee arthroplasty (TKA) or total 
hip arthroplasty (THA) surgery of which are proficient with the English language, any 
race, and are not legally blind or deaf. Inclusion criteria will be those undergoing TKA or 
THA surgery, between the ages of 18 and 60, an American Society of Anesthesiologists 
(ASA) physical status score of I or II (Appendix C), and that have received the standard 
preoperative kit. The standard preoperative prophylactic multimodel regimen will include 
oral metoclopramide (Reglan) 10 milligrams (mg) and oral famotidine (Pepcid) 20 mg 
the night before surgery and the morning of surgery, levoduboisine (Scopolamine) 1.5 mg 
transdermal patch the morning of surgery and ondansetron (Zofran) 4 mg intravenously 
the morning of surgery. The standard anesthetic plan at the clinical institution shall 
include the use of a 0.75% bupivicaine (Marcaine) 7.5mg to 15mg with morphine 
(Duramorph) 100 micrograms (mcg) to 300 mcg spinal, intravenous induction with 
isopropylphenol (Propofol) 50mg to 200mg with lidocaine (Xylocaine) 20mg to 100mg 
for Laryngeal Mask Airway (LMA) insertion, and the use of sevoflurane (Ultane) or 
desflurane (Suprane) inhalational agent. Exclusion criteria would be those patients less 
than 18 or older than 60 years of age, ASA III or greater, hip or knee revisions, having 
blood loss greater than 500 milliliters (mls), or hypotension requiring the use of more 
than 1000 micrograms (mcg) of neosynephrine (Phenylephrine) intravenously or more 
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than 50 milligrams (mg) of Ephedrine intravenously. The addition of any other 
vasoactive medications would also exclude patients from this study as well as the patient 
not being able to communicate proficiently in the English language or being legally blind 
or deaf. The retrospective chart review will also make note of any anti-emetics and pain 
medications used preoperatively, intraoperatively and postoperatively and a positive 
indicator for early PONV is the administration of an antiemetic due to the complaint of 
nausea and/or vomiting while in the post anesthesia care unit from 0 to 6 hours after 
surgery. Information also included in the chart review shall include those items listed on 
the data collection tool in Appendix D. 
Methods 
After obtaining approval from the institutional review board (IRB) from the 
specialty facility IRB and the university IRB, the retrospective chart analysis will be 
initiated.  A retrospective analysis of de-identified electronic health record data will be 
performed using medical record abstraction using a data collection form (DCF) during 
the time frame ranging from March 1, 2015 to August 31, 2015. Information obtained on 
patients treated at the specialty facility in the Southeastern United States include variables 
of age, gender, height, weight, ASA classification, comorbidities, type of surgery, length 
of surgery, type and administration amount of each medication used preoperatively, 
intraoperatively, and postoperatively, inhalation agent used, oral adjunct used,  blood 
loss, and fluid administered. A positive indicator for early PONV is the administration of 
an antiemetic due to the complaint of nausea and/or vomiting while in the post anesthesia 
care unit from 0 to 6 hours after surgery. 
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Confidentiality of records will be maintained throughout the collection of data 
from the electronic health record, and the subjects will remain unidentifiable. Information 
obtained will be analyzed by using a standard statistical program and performing a one-
sample t-test, a one-sided t- test. The percentage of patients experiencing PONV will be 
determined and compared to the expected incidence of PONV using the Apfel and 
Koivuranta PONV Scoring Systems. The occurrence of nausea in each age will then be 
calculated using chi-square test to determine if there is significance between age and 
prevention or occurrence of PONV. If there is a profound significance found between the 
ages, ages will be grouped and further testing will be completed to offer substantial data. 
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CHAPTER IV 
ANALYSIS OF DATA 
 The intended purpose of this project was to determine the efficacy of a 
preoperative multimodal antiemetic regimen on reducing early postoperative nausea and 
vomiting (PONV) in total arthroplasty patients. This determination would be obtained 
performing a retrospective chart examination, collection of vital information related to 
PONV on a data collection tool, comparison of actual versus expected percentages of 
PONV, and statistical analysis of the information. The data analyzed is classified 
accordingly as follows: 1) Data Analysis, 2) Presentation of Findings. 
Data Analysis 
 In order to determine the efficacy of a preoperative multimodal antiemetic 
regimen on early PONV, information obtained in relation to the Apfel and Koivuranta 
risk scores were categorized and given numeric values. Each patient was given a score 
according to the number of risk factors for PONV in relation to the Apfel and Koivuanta 
scales which correlated to a certain risk percentage. These patients were then identified as 
either having PONV or not having PONV. The total expected percentage of patients to 
exhibit PONV were then calculated as well as the actual total percentage of patients that 
exhibited PONV. These two numbers were then compared using a one sample t-test to 
determine if they were significantly different. The one sample t-test is used to determine 
the level of significance between a tested outcome of a group when compared to a known 
standard and can be used for a sample of 30 or less (Daniel, 2009). An actual percentage 
of patients that exhibited PONV were then found using a Statistical Package for the social 
sciences (SPSS). Use of a Pearson’s chi-square test and a Fisher’s exact test were then 
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used to determine the significance of the findings. A Pearson’s chi-square test is the most 
frequently used statistical tool for analysis of frequency or to count data and can 
determine the relationship between two categories (Daniel, 2009). Pearson’s chi-square 
tests are used when sample sizes are large while Fisher’s exact tests are used when 
sample sizes are small (Daniel, 2009).  The level of significance found by using the 
Pearson’s chi-square test and the Fisher’s exact test determined if the findings are 
significant or not. Level of significance, also known as alpha, is the probability of 
rejecting a true null hypothesis (Daniel, 2009). The alpha used in this study was equal to 
0.05, which is the maximum level of significance used in scientific research (Daniel, 
2009). Alpha was used to identify whether or not the multimodal preoperative kit is 
effective in treating early PONV in this surgical population. The population was also 
tested for significance in relation to age and PONV by using a cross tabulation Pearson’s 
chi-square test as well as a Fisher’s exact test. For this project a hypothesis and null 
hypothesis were formed. The hypothesis for this capstone was: there is no difference in 
the incidence of early postoperative nausea and vomiting in total knee arthroplasty (TKA) 
and total hip arthroplasty (THA) patients with the administration of a preoperative 
multimodal antiemetic kit when compared to no antiemetic use.  
Presentation of Findings 
 The retrospective chart analysis was completed at a specialty facility in the 
Southeast region of the United States. It was conducted over a six month time frame on 
50 patients between the ages of 24-60, undergoing total knee arthroplasty (TKA) or total 
hip arthroplasty (THA) surgery. All patients included in the study met previously stated 
inclusive criteria, including but not limited to, receiving the standardized preoperative 
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anti-emetic kit, acquiring the American Society of Anesthesiologists (ASA) physical 
health score of I or II, undergoing a spinal anesthetic as well as a laryngeal mask airway 
general anesthetic with medications associated with each, and not incurring 
overwhelming amounts of blood loss or hypotension. 
 The retrospective chart analysis was completed and pertinent information was 
transferred to a paper data collection tool (DCT). Confidentiality of patient information 
was maintained and all data was de-identified in the collection and transfer process. Once 
the information was categorized, given numeric values, and applied to statistics, the paper 
DCTs were then destroyed. Patient demographic characteristics related to this study can 
be found in Table 1.  
Table 1 
Demographic Characteristics of Patients 
________________________________________________________________________ 
Characteristic    Number   Percentage 
________________________________________________________________________ 
 
Gender 
     Male    26    52 
     Female    24    48 
 
Age (years) 
     Mean    52.5  
     Range    24 – 60 
 
Smoker    5    10  
Non-Smoker    45    90 
 
________________________________________________________________________ 
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Table 1 (continued). 
________________________________________________________________________ 
 
 
Characteristic    Number   Percentage 
 
________________________________________________________________________ 
 
History of PONV   3    6 
 
No History of PONV   47    94 
 
No History of Motion Sickness 50    100 
 
Postoperative Opioids   47    94 
 
No Postoperative Opioids  3    6 
 
Duration of Surgery > 1 hour  100    100 
 
________________________________________________________________________ 
 
 With the use of the Apfel PONV Risk Scoring System, patients were given a 
score related to the number of risk factors present, which in turn corresponded to the 
expected risk of experiencing PONV. The Apfel Risk Factor Score and corresponding 
percentage, as well as frequency and valid percentage numbers for patients in each 
category can be seen below in Table 2. Most of the patients fall in the risk factor score of 
2 and 3 which equates to 20% and 40% corresponding risk.  
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Table 2 
Apfel Risk Scoring System-Frequency of Patients 
________________________________________________________________________ 
 
 
Apfel Risk Factor Score Corresponding Risk % Patient Frequency   Valid % 
 
________________________________________________________________________ 
  
0    10%    0   0 
 
1    20%    4   8 
 
2    40%    25   50 
 
3    60%    19   38 
 
4    80%    2   4 
 
________________________________________________________________________ 
 
 With the use of the Koivurnata PONV Risk Scoring System, patients were given a 
score related to the number of risk factors present which in turn corresponded to the 
expected risk of experiencing PONV. The Koivuranta risk factor score and corresponding 
percentage, as well as frequency and valid percentage numbers for patients in each 
category can be seen below in Table 3.  Most of the patients fall in the risk factor score of 
2 and 3 which equals 42% and 54% corresponding risk. 
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Table 3 
Koivuranta Risk Scoring System-Frequency of Patients 
________________________________________________________________________ 
 
Koivuranta Risk Factor Score      Corresponding Risk %     Patient Frequency       Valid % 
 
________________________________________________________________________ 
 
0         17%   0   0 
1         18%   1   2 
 
2         42%   28   56 
 
3         54%   19   38 
 
4         74%   2   4 
 
5         87%   0   0 
________________________________________________________________________ 
 After the chart review, it was noted that only 8 of the 50 patients experienced 
early PONV. Of the 8 patients whom experienced early PONV, 6 were female and 2 were 
male. Ages ranged from 48 to 60, with all but one being a non-smoker, one having a 
history of PONV, and all receiving postoperative opioids. Demographics of these patients 
can be seen in Table 4. Table 5 is a representation of the frequency of those whom 
experienced PONV as an actual total percentage of the overall population. 
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Table 4 
Demographic Characteristics of Patients Whom Experienced Early PONV 
________________________________________________________________________ 
Gender           Age         Non-Smoker       History of PONV       Postoperative Opioids      
 
_______________________________________________________________________ 
 
Female           48              Yes                    No                             Yes 
Female           50              Yes                    No                             Yes 
Female           51              Yes                    Yes                            Yes 
Female           52              No                     No                             Yes 
Female           56              Yes                    No                             Yes 
Female           59              Yes                    No                             Yes 
Male              53              Yes                    No                              Yes 
Male              60              Yes                    No                              Yes 
_______________________________________________________________________ 
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Table 5 
Frequency of PONV 
________________________________________________________________________ 
 
PONV (Yes or No)   Patient Frequency  Actual Total %  
 
________________________________________________________________________ 
  
Y     8    16 
 
N     42    84 
___________________________________________________________________________________________________________ 
 
Note. Y=Yes, N=No 
 
 The expected total percentage was found for both the Apfel and Koivuranta 
PONV Scoring Systems. The results showed an expected total percentage of PONV to be 
47.6% using the Apfel Score, and an expected total percentage of PONV was 47.4% 
using the Koivuranta Score. The actual total percentage was found to be 16%. The actual 
total percentage given in Table 5 was then placed with the expected total percentage for 
comparison in Table 6. 
Table 6 
Expected and Actual Total Percentage of PONV for Apfel and Koivuranta PONV Scoring 
System 
________________________________________________________________________ 
Scoring System Expected Total % of PONV  Actual Total % of PONV 
________________________________________________________________________ 
Apfel   47.6     16 
 
Koivuranta  47.4     16 
________________________________________________________________________ 
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 A one-sided t-test was then used to determine if the actual total percentage of 
PONV was significantly different than the expected total percentage of PONV in both the 
Apfel and Koivuranta systems. The null hypothesis is that the difference between the 
expected total percentage of PONV and the actual total percentage of PONV is zero. The 
conclusion at the 0.05 critical alpha level is that the data revealed a significant difference 
between the actual total percentage of PONV and the expected total percentage of PONV 
for both scoring systems which can be seen in Table 7. 
Table 7 
One-Sided T-Test for Actual and Expected Total Percentage for PONV 
________________________________________________________________________ 
 
Risk Scoring System t-statistic df              Two-tailed probability (p-value) 
 
________________________________________________________________________ 
 
Apfel            3.052  49  .004 
 
Koivuranta      3.034  49  .004 
 
________________________________________________________________________ 
 
Note. df=degrees of freedom 
 
 The numbers of expected and actual patients with PONV for each risk factor were 
then found using a cross-tabulation in SPSS for both the Apfel and Koivuranta PONV 
Risk Scoring Systems. In the Apfel system the number of patients expected to experience 
PONV for risk factor scores of 0 through 4 were: 0, 1, 10, 11, and 2 respectively. The 
actual number of patients whom experienced PONV for each risk factor scores of 0 
through 4 were: 0, 0, 3, 4, and 1 respectively. In the Koivuranta system the number of 
patients expected to experience PONV for risk factor scores 0 through 5 were: 0, 0, 12, 
10, 1, and 0 respectively. The actual number of patients whom experienced PONV for 
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each risk factor scores of 0 through 4 were: 0, 0, 3, 4, 1, 0. Table 8 is a representation of 
such. 
Table 8 
Numbers of Expected and Actual Patients with PONV for each Risk Factor for Apfel and 
Koivuranta PONV Risk Scoring Systems 
________________________________________________________________________ 
Risk Scoring System    Risk Factors        PONV Expected                  PONV Actual     
 
_______________________________________________________________________ 
Apfel                            0                           0                                            0 
                                     1                           1                                            0 
                                     2                           10                                          3 
                                     3                           11                                          4 
                                     4                           2                                            1 
Koivuranta                   0                           0                                            0 
                                     1                           0                                            0 
                                     2                           12                                          3 
                                     3                           10                                          4 
                                     4                           1                                            1 
                                     5                           0                                            0 
_______________________________________________________________________ 
 The percentages of the expected and actual patients with PONV for each risk 
factor were then found using a cross-tabulation in SPSS for both the Apfel and 
Koivuranta PONV Risk Scoring Systems. These percentages can be seen in Table 9.  
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Table 9 
Percent of Expected and Actual Patients with PONV for each Risk Factor for Apfel and 
Koivuranta PONV Risk Scoring Systems 
________________________________________________________________________ 
Risk Scoring System    Risk Factors     PONV Expected Percent    PONV Actual Percent     
 
_______________________________________________________________________ 
 
Apfel                            0                        0%                                         0% 
                                     1                        20%                                       0% 
                                     2                        40%                                       12% 
                                     3                        60%                                       21% 
                                     4                        80%                                       50% 
Koivuranta                   0                        0%                                         0% 
                                     1                        18%                                       0% 
                                     2                        42%                                       11% 
                                     3                        54%                                       21% 
                                     4                        74%                                       50% 
                                     5                        87%                                       0% 
_______________________________________________________________________ 
           The results of the expected and actual patients with PONV for each risk factor 
were then compared for both the Apfel and Koivuranta PONV Scoring Systems to 
determine if the decrease in PONV were significant. In both the Apfel and Koivuranta 
PONV Scoring Systems, patients found to exhibit 2 or 3 risk factors were shown to have 
a significant decrease in PONV. The results can be visualized in Table 10. 
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Table 10 
Significance of Expected and Actual Patients with PONV for each Risk Factor for Apfel 
and Koivuranta PONV Risk Scoring Systems 
________________________________________________________________________ 
Risk System    Risk Factors      Value           df          p-value        Fisher’s Test        Sig. 
 
_______________________________________________________________________ 
 
 
Apfel                 0                        0                 0             0                  0                          N 
                          1                        1.143          1             0.1425         0.5000                 N 
                          2                        5.094          1             0.0120         0.0253                 Y 
                          3                        5.397          1             0.0101         0.0224                 Y 
                          4                        1.333          1             0.1241         0.5000                 N 
_______________________________________________________________________ 
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Table 10 (continued). 
_______________________________________________________________________ 
Risk System    Risk Factors      Value           df          p-value        Fisher’s Test        Sig. 
 
_______________________________________________________________________ 
 
Koivuranta        0                        0                  0           0                   0                         N 
                          1                        2                  1           0.0786          0.5000                N 
                          2                        7.376           1           0.0033          0.0071                Y 
                          3                        4.071           1           0.0218          0.0455                Y 
                          4                        0                  1           0.5000          0.8333                N 
                          5                        0                  0           0                   0                         N 
_______________________________________________________________________
Note.  df=Degrees of Freedom, p-value=Pearson’s one tailed Probability, Sig=Significance 
          The age groups of those who experienced PONV were then entered into SPSS to 
calculate if there was any relation between age and nausea, which was determined not to 
be significant with a p-value of 0.370. The numbers of individual risk factors were also 
compared to the incidence of PONV for both risk scoring systems which gave an Apfel 
p-value of 0.370 and a Koivuranta p-value of 0.415. Both of which are not significant. 
Therefore there was not a significant difference in PONV found between the patients 
with different numbers of characteristics for PONV.  
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CHAPTER V 
SUMMARY 
 The purpose of this capstone project was to determine if there was a significant 
effectiveness of a preoperative multimodal antiemetic regimen on reducing early 
postoperative nausea and vomiting (PONV) in total hip arthroplasty (THA) and total knee 
arthroplasty (TKA) patients. Through the use of a retrospective chart analysis on 50 
patients undergoing THA and TKA surgeries at a location in the Southeastern United 
States, information regarding this topic was concluded. Organization of this chapter is as 
follows: 1) Results, 2) Cost Implications, 3) Recommendations, and 4) Conclusions. 
Results 
 After completing a statistical analysis on all the data gathered, with comparison to 
the expected Apfel and Koivuranta Risk Scale Scores for PONV, results showed a 
significant decrease in early PONV with the administration of a preoperative multimodal 
kit in THA and TKA patients who had 2 and 3 risk factors for PONV. There was no 
significant decrease found in early PONV with those patients with 1 and 4 risk factors for 
PONV. Results were not able to be determined for those patients with 0 and 5 risk factors 
since there were no patients available for study with 0 and 5 risk factors. Results also 
showed an overall total percentage decrease in early PONV from 47% to 16% for both 
scales with the administration of a preoperative multimodal kit in THA and TKA 
patients.  
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Cost Implications 
 The cost to an ambulatory surgery center for the treatment of acquired PONV can 
be approximated to over $1000 US currency per patient (Sanchez, Hirsch, Carroll, & 
Miederhoff, 1994). According to the specialty facility in the Southeastern United States, 
the cost of the preoperative multimodal kit is $21.60 per patient. The cost of the 
preoperative multimodal regimen to the surgical center is miniscule in relation to the 
potential cost of a patient acquiring PONV. Along with a potential savings in monetary 
cost, the overall health and mental wellbeing of the patient is also protected. 
Recommendations 
 This capstone study has revealed a significant decrease in early PONV with the 
administration of a preoperative antiemetic multimodal regimen to patients with 2 or 3 
risk factors for the development of PONV, undergoing THA and TKA surgery, and 
receiving both a spinal and general anesthetic. Recommendations would be for the 
continued use of such a preoperative antiemetic regimen specific for these types of 
surgeries, for American Society of Anesthesiologists (ASA) I and II health score patients 
with 2 or 3 risk factors for PONV, ranging from the ages of 24 to 60, and given both a 
spinal and general anesthetic with laryngeal mask airway use (LMA). Future research 
could include a larger sample size and include an equal distribution of patients in each 
group of risk factors to determine the significance. Additional research could include 
patients older than 60 years of age, ASA score greater than III, and having other types of 
surgeries. 
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Conclusion 
 The findings of this retrospective analysis has confirmed a significant decrease in 
postoperative nausea and vomiting (PONV) with the use of a multimodal antiemetic 
regimen on patients who exhibit 2 and 3 known risk factors for PONV. This study did 
also not establish a significant decrease in PONV on patients who exhibit 0, 1, 4, or 5 
known risk factors for PONV. This may be attributed to either the small sample size of 
those patients, a decreased risk for developing PONV, or being at such a large risk for 
developing PONV. Overall this analysis should encourage stakeholders and anesthesia 
providers to support the use of preoperative antiemetic regimens not only for the purpose 
of controlling the establishment’s monetary loss but to protect the patient from 
unnecessary risk, harm, and suffering.  
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CHAPTER VI 
ESSENTIALS 
The Essentials of Doctoral Education for Advanced Nursing Practice 
I. Scientific Underpinnings for Practice  
 The benefit to anesthesia will be improved patient outcomes by 
identifying those at risk for PONV, reducing the occurrence of PONV, 
and improving patient outcomes. The knowledge obtained from this 
study will help decrease cost related to adverse outcomes related to 
PONV. 
II. Organizational and Systems Leadership for Quality Improvement and Systems 
 Research supports that the use of preoperative antiemetic medications 
reduces the incidence on PONV. The administration of a multimodal 
regimen should improve the quality of care the patient receives, 
especially in those that are at a higher risk for PONV. 
III. Clinical Scholarship and Analytical Methods for Evidence-Based Practice 
 Research supports that preoperative prophylactic antiemetic use leads 
to a reduction in PONV. The results of this study can show a 
multimodal use for a particular surgical population that can be applied 
to other areas of surgery.  
IV. Information Systems/Technology and Patient Care Technology for the 
Improvement and Transformation of Health Care 
 The use of a research database has led to a large source of knowledge 
that can be accessed easily and rapidly. SPSS can be used to assist in 
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quantifying data. The use of electronic records makes gathering of 
patient information easy. Use of electronic charting allows for the 
rapid categorizing of data as well as more legible information. 
V. Health Care Policy for Advocacy in Health Care 
 Evidence supports that a reduction of PONV leads to less occurrence 
of adverse outcomes. Standards of care exist for many areas of 
healthcare while standards for PONV do not seem to be present. 
VI. Inter-professional Collaboration for Improving Patient and Population Health 
Outcomes 
 Caring for a surgical patient requires collaboration and teamwork from 
many different individuals with many different job titles. It is vital that 
each individual perform according to their job description to provide 
the best care possible. 
VII. Clinical Prevention and Population Health for Improving the Nation’s Health 
 A reduction of PONV will not only lead to an increase in patient 
satisfaction but also a decrease in cost to the patient and institution. A 
reduction in PONV will lead to shorter hospital stays, less readmits, 
less adverse outcomes in relation to PONV, and less morbidity and 
mortality. 
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APPENDIX A 
APFEL RISK SCORE FOR PONV 
(Apfel et al., 2002) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk Factor Points 
Female Gender 1 
Non-Smoker 1 
History of PONV 1 
Postoperative Opioids 
----------------------------- 
Sum 
 
Sum of 0 points= 10% Risk for PONV 
Sum of 1 point =  20% Risk for PONV 
Sum of 2 points= 40% Risk for PONV 
Sum of 3 points= 60% Risk for PONV 
Sum of 4 points= 80% Risk for PONV 
1 
------ 
0-4 
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APPENDIX B 
KOIVURANTA RISK SCORE FOR PONV 
(Koivuranta et al., 1997) 
 
 
 
 
 
 
 
 
 
 
 
Risk Factor Points 
Female Gender 1 
Non-Smoker 1 
History of PONV 1 
History of Motion Sickness 
 
Duration of Surgery >60 minutes 
----------------------------- 
Sum 
 
Sum of 0 point =  17% Risk for PONV 
Sum of 1 point =  18% Risk for PONV 
Sum of 2 points= 42% Risk for PONV 
Sum of 3 points= 54% Risk for PONV 
Sum of 4 points= 74% Risk for PONV 
Sum of 5 points= 87% Risk for PONV 
1 
 
1 
------ 
0-5 
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APPENDIX C 
AMERICAN SOCIETY OF ANESTHESIOLOGISTS PHYSICAL CLASSIFICATION  
ASA PS 
Classification 
Definition 
Examples, including, but not limited 
to:  
ASA I A normal healthy patient Healthy, non-smoking, no or minimal 
alcohol use 
ASA II A patient with mild systemic 
disease 
Mild diseases only without substantive 
functional limitations. Examples 
include (but not limited to): current 
smoker, social alcohol drinker, 
pregnancy, obesity (30 < BM < 40), 
well controlled DM/HTN, mild lung 
disease  
ASA III A patient with severe systemic 
disease 
Substantive functional limitations; One 
or more moderate to severe diseases. 
Examples include (but not limited to): 
poorly controlled DM or HTN, COPD, 
morbid obesity (BMI ≥40), active 
hepatitis, alcohol dependence or 
abuse, implanted pacemaker, 
moderate reduction of ejection fraction, 
ESRD undergoing regularly scheduled 
dialysis, premature infant PCA < 60 
weeks, history (>3 months) of MI, 
CVA, TIA, or CAD/stents.  
ASA IV A patient with severe systemic 
disease that is a constant threat 
to life 
Examples include (but not limited to): 
recent ( < 3 months) MI, CVA, TIA, or 
CAD/stents, ongoing cardiac ischemia 
or severe valve dysfunction, severe 
reduction of ejection fraction, sepsis, 
DIC, ARD or ESRD not undergoing 
regularly scheduled dialysis 
ASA V A moribund patient who is not 
expected to survive without the 
operation 
Examples include (but not limited to): 
ruptured abdominal/thoracic 
aneurysm, massive trauma, 
intracranial bleed with mass effect, 
ischemic bowel in the face of 
significant cardiac pathology or 
multiple organ/system dysfunction 
ASA VI  A declared brain-dead patient 
whose organs are being 
removed for donor purposes 
  
(American Society of Anesthesiologists, 2015) 
37 
 
APPENDIX D 
 
DATA COLLECTION FORM 
 
Identification # __________ Procedure Date  __/__/____  
Age  _______ Sex  M  / F Ht.  _____   Wt.  _______ BMI ________  
Ethnicity  ______________ Smoker Y/N     ASA __________ 
Current Medications  ______________________________________________________ 
________________________________________________________________________ 
Past Medical History_______________________________________________________ 
________________________________________________________________________ 
Previous Surgeries  _______________________________________________________ 
Past Anesthesia Complications ______________________________________________ 
Preoperative medications___________________________________________________ 
Anes Start  _____________ Anes End  _____________ Total Anes  ____________ 
Surgery Start  ___________ Surgery End  ___________ Total Surgery  __________ 
Spinal: 
Level ____________ Local Anesthetic _____________ Dose______________ 
Intraoperative: 
Airway Type ________________ Airway Size ___________________ 
Time Medication Dose Vital Signs 
    
    
    
    
    
    
    
    
    
    
 
IVF type:  _____________ 
 
Total IVF:  ______ mL   
EBL __________ml 
 
PACU: 
PACU Vital Signs:  
 
BP _____  HR _____ Temp ____ 
 
 
 
 
 
SaO2 ____ RR ____  PACU in____ out______ 
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APPENDIX E 
UNIVERSITY OF SOUTHERN MISSISSIPPI IRB APPROVAL LETTER 
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APPENDIX F 
FORREST GENERAL HOSPITAL IRB EXEMPT STATUS 
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